Follistatin 344

What it is?

Follistatin 344 is studied for its interaction with myostatin regulation, a pathway commonly described as a physiological “brake” on muscle growth. By influencing this mechanism, it is positioned for muscle-development signalling research.

Dripfy Advantage

• Myostatin pathway modulation: Binds to and neutralises myostatin-associated signalling, a key regulator that limits muscle growth.
• Receptor-level impact: Reduces activation of growth-inhibitory pathways commonly linked to ActRIIB / SMAD signalling.
• Myogenesis support: Supports cellular signalling associated with muscle formation and tissue remodelling.
• Anti-catabolic bias: May suppress pathways linked to muscle breakdown under stress or atrophy-relevant models.
• Synergy positioning: Often stacked in protocols where growth-factor signalling and myostatin control are complementary endpoints.

Clinical Applications & Therapeutic Potential

• Myostatin pathway modulation: Inhibition of myostatin-associated signalling, supporting an anabolic-biased environment.
• Muscle tissue remodelling: Support for myogenesis-related signalling and structural regeneration markers.
• Anti-catabolic profile: Reduction in muscle breakdown signalling under high training stress or atrophy models.
• Composition-focused endpoints: Support for increased lean-mass signalling and improved muscle maintenance dynamics.

Composition & Formulation

• Peptide content: 1 mg Follistatin-344
• Vehicle: Proprietary protein-stabilizing solution
• Delivery system: Pre-filled, multi-dose, closed-system pen
• Total volume: 3 mL
• Purity: ≥95% by SDS-PAGE analysis